Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Does GLP-1 use result in significant hair loss? | Well actually | The Guardian (opens in a new tab)

theguardian.com · 2026-09-27

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

19 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • Points somewhere elsepresented as the new finding

    Dermatological, Trichological and Quality of Life Consequences of GLP ‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey

    Journal of Cosmetic Dermatology · 2026

    Publisher (opens in a new tab)
  • Cited as backgroundpresented as the new finding

    GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling

    Science Progress · 2026

    PubMed (opens in a new tab)Full Tessa analysis (opens in a new tab)
The literature search

19 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 15 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedIn one survey of people who take these medications, 20% of respondents experienced hair shedding, although the article says the lack of high-quality randomized controlled trial data makes it difficult to know exactly how common the side-effect is.View evidenceHide evidence

As stated20% of respondents

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedAbout 20 million people across the US, UK, and EU are taking GLP-1 receptor agonists like tirzepatide and semaglutide for weight loss and type 2 diabetes, and researchers are learning more about side-effects including hair loss.View evidenceHide evidence

As statedAbout 20 million people

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedMost people who take GLP-1 drugs do not have hair loss, but those who do often notice it within the first year, usually peaking a little before month 12.View evidenceHide evidence

As statedwithin the first year; peaking a little before the 12th month

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedA recent study led by Lynn Petukhova found that men taking GLP-1 drugs were 7% more likely to experience pattern baldness than men not taking the drugs, and the study could not assess the risk in women.View evidenceHide evidence

As stated7% more likely

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedOne study found that white patients were more likely to report hair shedding and thinning, while Black patients more commonly reported hair dryness and breakage.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe article says telogen effluvium on GLP-1 drugs may be caused by rapid weight loss and micronutrient deficiencies, and that tirzepatide and semaglutide at higher doses had the highest rates of temporary hair loss.View evidenceHide evidence

As statedhighest rates

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Dermatological, Trichological and Quality of Life Consequences of GLP ‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey

Journal of Cosmetic Dermatology · 2026 · Crossref

Source (opens in a new tab)
Candidate

Review for "Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety"

2025 · Crossref

Source (opens in a new tab)

Explore all search results